Isotretinoin
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 1 | CCC |
Vorinostat National Cancer Institute (NCI) | Phase 1 | CCC |
Plerixafor Lawrence Recht | Phase 1/2 | CCC |
View all 30 →
Same molecule, other indications
Isotretinoin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →